Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Recursion Pharmaceuticals Inc shares valued at $471,000 were sold by Gibson Christopher on Sep 10 ’25. At $4.71 per share, Gibson Christopher sold 100,000 shares. The insider’s holdings dropped to 974,229 shares worth approximately $4.8 million following the completion of this transaction.
Also, Gibson Christopher purchased 100,000 shares, netting a total of over 471,000 in proceeds.
Before that, Gibson Christopher had sold 100,000 shares from its account. In a trade valued at $484,000, the Chief Executive Officer traded Recursion Pharmaceuticals Inc shares for $4.84 each. Upon closing the transaction, the insider’s holdings decreased to 100,000 shares, worth approximately $4.7 million.
Analysts at Morgan Stanley started covering the stock with ‘”an Equal-weight”‘ outlook in a report released in late May. As of March 16, 2023, Needham has initiated its “Buy” rating for RXRX. Earlier on September 16, 2022, KeyBanc Capital Markets initiated its rating. Their recommendation was “an Overweight” for RXRX stock.
Analyzing RXRX Stock Performance
On last trading session, Recursion Pharmaceuticals Inc [NASDAQ: RXRX] rose 4.67% to $4.93. The stock’s lowest price that day was $4.79, but it reached a high of $4.97 in the same session. During the last five days, there has been a surge of approximately 1.65%. Over the course of the year, Recursion Pharmaceuticals Inc shares have dropped approximately -25.86%.
Is Recursion Pharmaceuticals Inc subject to short interest?
Stocks of Recursion Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-29 jumping by 6.54 million shares to 124.08 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 117.54 million shares. A jump of 5.27% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.82 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.82.
Which companies own the most shares of Recursion Pharmaceuticals Inc (RXRX)?
In terms of Recursion Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 8.5 in the next 12 months, up nearly 80.47% from the previous closing price of $4.71. Analysts anticipate Recursion Pharmaceuticals Inc stock to reach 12 by 2025, with the lowest price target being 6. In spite of this, 3 analysts ranked Recursion Pharmaceuticals Inc stock as Buy at the end of 2025. On April 18, 2022, BofA Securities assigned a price target of “a Neutral” to the stock and downgraded coverage with a $10.
